Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5262
Abstract: Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in castration‐resistant… read more here.
Keywords: prostate cancer; resistant prostate; real world; castration resistant ... See more keywords
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-017-1176-0
Abstract: BackgroundRadium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic… read more here.
Keywords: japanese patients; 223 dichloride; radium 223; prostate cancer ... See more keywords
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-018-01389-4
Abstract: BackgroundRadium-223 is a first-in-class targeted alpha therapy to prolong overall survival (OS) in castration-resistant prostate cancer with bone metastases (mCRPC). The aim of the present analysis was to assess the long-term safety with radium-223 in… read more here.
Keywords: bone metastases; radium 223; study; japanese patients ... See more keywords
Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-020-01776-w
Abstract: Background Radium-223 (Ra-223) is a targeted alpha therapy that has been shown to prolong overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. However, prognosis after Ra-223 administration varies among… read more here.
Keywords: bone metastases; radium 223; prostate cancer; bone ... See more keywords
Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
Sign Up to like & getrecommendations! Published in 2017 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-017-1785-0
Abstract: Despite the improvement provided by androgenic suppression in the treatment of prostate cancer, most of tumors develop resistance to castration. However, new therapies have demonstrated an increase in patient survival such as radium-223 (Ra-223), an… read more here.
Keywords: castration; treatment; radium 223; prostate cancer ... See more keywords
Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Nuclear Medicine"
DOI: 10.1007/s12149-018-1317-1
Abstract: Radium-223 dichloride (Ra-223) is the first targeted alpha therapy approved for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastasis. Ra-223 improved overall survival in the international Phase III ALSYMPCA (ALpharadin in… read more here.
Keywords: 223 clinical; radium 223; japan; targeted alpha ... See more keywords
Radium‐223 Use in Clinical Practice and Variables Associated With Completion of Therapy
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2016.08.015
Abstract: Micro‐Abstract Radium‐223 has shown improvements in overall survival in men with metastatic castration‐resistant prostate cancer (mCRPC). In this study, we investigated clinical variables associated with radium‐223 therapy completion in mCRPC. We show the previous and… read more here.
Keywords: radium; completion; radium 223; variables associated ... See more keywords
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2017.08.020
Abstract: Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for… read more here.
Keywords: radium; radium 223; prostate cancer; use radium ... See more keywords
Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Sign Up to like & getrecommendations! Published in 2017 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2017.03.001
Abstract: Radium-223, a calcium mimetic bone-seeking radionuclide that selectively targets bone metastases with alpha particles, is approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. In patients with mCRPC,… read more here.
Keywords: radium; treatment; radium 223; metastatic castration ... See more keywords
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer"
DOI: 10.1016/j.ejca.2020.05.001
Abstract: PURPOSE Radium-223 is a targeted alpha radiation therapy for metastatic castration-resistant prostate cancer. DNA damage repair (DDR) defective prostate cancers, specifically genetic aberrations leading to homologous recombination deficiency (HRD), accumulate irreparable DNA damage following genotoxic… read more here.
Keywords: prostate; dna damage; radium; radium 223 ... See more keywords
Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit.
Sign Up to like & getrecommendations! Published in 2019 at "European urology"
DOI: 10.1016/j.eururo.2019.01.026
Abstract: Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this… read more here.
Keywords: combined radium; radium 223; prostate cancer; higher risk ... See more keywords